Rydex Biotechnology Fund Class Investor
RYOIX
NASDAQ
Weiss Ratings | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Reward Grade | C | |||
Risk Index | Fair | |||
Risk Grade | C | |||
Company Info | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Provider | Rydex Funds | |||
Manager/Tenure (Years) | Michael P. Byrum (27), Adrian Bachman (2), Brendan Cain (2), 2 others | |||
Website | http://www.guggenheiminvestments.com | |||
Fund Information | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Fund Name | Rydex Biotechnology Fund Class Investor | |||
Category | Health | |||
Sub-Category | Healthcare Sector Equity | |||
Prospectus Objective | Specialty - Technology | |||
Inception Date | Apr 01, 1998 | |||
Open/Closed To New Investors | Open | |||
Minimum Initial Investment | 2,500.00 | |||
Minimum Subsequent Investment | -- | |||
Front End Fee | -- | |||
Back End Fee | -- | |||
Dividends and Shares | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield | 0.00% | |||
Dividend | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Yield (Forward) | 0.80% | |||
Asset Allocation | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash | 3.54% | |||
Stock | 99.82% | |||
U.S. Stock | 94.85% | |||
Non-U.S. Stock | 4.97% | |||
Bond | 0.00% | |||
U.S. Bond | 0.00% | |||
Non-U.S. Bond | 0.00% | |||
Preferred | 0.00% | |||
Convertible | 0.00% | |||
Other Net | -3.37% | |||
Price History | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -1.51% | |||
30-Day Total Return | 1.98% | |||
60-Day Total Return | 6.20% | |||
90-Day Total Return | 3.76% | |||
Year to Date Total Return | 2.97% | |||
1-Year Total Return | -4.77% | |||
2-Year Total Return | 12.14% | |||
3-Year Total Return | 12.06% | |||
5-Year Total Return | 6.65% | |||
Price | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Closing Price | -- | |||
1-Month Low Price | -- | |||
1-Month High Price | -- | |||
52-Week Low Price | -- | |||
52-Week Low Price (Date) | -- | |||
52-Week High Price | -- | |||
52-Week High Price (Date) | -- | |||
NAV | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Nav | $66.41 | |||
1-Month Low NAV | $64.24 | |||
1-Month High NAV | $67.69 | |||
52-Week Low NAV | $55.59 | |||
52-Week Low NAV (Date) | Apr 08, 2025 | |||
52-Week High NAV | $82.61 | |||
52-Week High Price (Date) | Aug 21, 2024 | |||
Beta / Standard Deviation | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.74 | |||
Standard Deviation | 16.33 | |||
Balance Sheet | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Total Assets | 82.73M | |||
Operating Ratios | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Expense Ratio | 1.40% | |||
Turnover Ratio | 79.00% | |||
Performance | RYOIX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Last Bull Market Total Return | 15.13% | |||
Last Bear Market Total Return | -10.24% | |||